Cryoviva and Reviva Cell donate 50 million baht to Chulalongkorn University's medical research fund to advance Advanced Therapy Medicinal Products (ATMPs) including cell therapy and gene therapy. The initiative aims to establish Thailand as a regional hub for cellular drug development, with Chulalongkorn's ATMP center being the only GMP PIC/S-certified facility in Thailand for cell therapy production. Current focus includes clinical trials for mesenchymal stem cell treatments for knee osteoarthritis under the Health Ministry's ATMP Sandbox program.